Abstract
Rotavirus, the most common cause of gastroenteritis among children worldwide, is responsible for approximately 600,000 deaths every year worldwide. Clinical trials of RotaTeq and Rotarix, two commercially generated approved vaccines, have shown a high degree of effectiveness in protecting the most vulnerable individuals against rotavirus infections. RotaTeq and Rotarix are now incorporated into the portfolio of vaccines recommended for regular use by infants in the US and Mexico, respectively. The focus here is to evaluate the impact of vaccine-generated herd immunity, a function of the implementation regimes and coverage policies, on rotavirus transmission dynamics at the population level. In order to evaluate the overall impact of vaccine regimes in the US and Mexico, we develop an age-structured epidemiological model of rotavirus transmission that includes age-specific vaccination rates. This model is parameterized using available epidemiological and vaccine data. Numerical simulations of the parameterized model support the conclusion that reasonable rotavirus vaccination programs can prevent a significant fraction of primary (severe) rotavirus infections in the US and Mexico. Vaccination is likely to have stronger positive impact in Mexico than in the US, because the prevalence of rotavirus infections is higher in Mexico and demographics are distinct in two countries. It is shown that the age distribution of rotavirus cases will shift as a result of vaccination. This shift will be accompanied with decreases in the proportion of primary infections and the change in the distribution of subsequent infections. Effective vaccination regimes tend to increase the average age of both primary and subsequent infections. The observed shifts reduce the average population risk because severity tends to decrease with age.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson, R. M.,& May, R. M. (1985). Age-related changes in the rate of disease transmission: implications for the design of vaccination programmes. J Hygiene 94: 365–436.
Bresee, J. S., Parashar, U. D., Widdowson, M. A., Gentsch, J. R., Steele, A. D., & Glass, R. I. (2005). Update on rotavirus vaccines. Pediatr Infect Dis J 24(11):947–952.
CDC. (2008). Statistics and Surveillance: July 2006–June 2007 Table Data (Publication. Retrieved May 27, 2008: http://www.cdc.gov/vaccines/stats-surv/nis/data/tables_0607.htm
Clark, H. F., Bernstein, D. I., Dennehy, P. H., Offit, P., Pichichero, M., Treanor, J., et al. (2004). Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 144(2):184–190.
Delayed onset and diminished magnitude of rotavirus activity – United States, November 2007–May 2008. (2008). MMWR Morb Mortal Wkly Rep 57(25):697–700.
Dennehy, P. H. (2008). Rotavirus vaccines: An overview. Clin Microbiol Rev 21(1), 198–208.
Dennehy, P. H., Cortese, M. M., Begue, R. E., Jaeger, J. L., Roberts, N. E., Zhang, R., et al. (2006). A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in US children. Pediatr Infect Dis J 25(12):1123–1131.
Glass, R. I., Bresee, J. S., Turcios, R., Fischer, T. K., Parashar, U. D., & Steele, A. D. (2005). Rotavirus vaccines: Targeting the developing world. J Infect Dis 192(Suppl 1):S160–166.
Glass, R. I., & Parashar, U. D. (2006). The promise of new rotavirus vaccines. N Engl J Med 354(1), 75–77.
Grimwood, K., & Bines, J. E. (2007). Rotavirus vaccines must perform in low-income countries too. Lancet 370(9601):1739–1740.
Hethcote, H. W. (1997). An age-structured model for pertussis transmission. Math Biosci 145(2):89–136.
Hethcote, H. W. (1999). Simulations of pertussis epidemiology in the United States: effects of adult booster vaccinations. Math Biosci 158(1):47–73.
Hethcote, H. W., Horby, P., & McIntyre, P. (2004). Using computer simulations to compare pertussis vaccination strategies in Australia. Vaccine 22(17–18):2181–2191.
International Data Base, Table 028. (2008). from http://www.census.gov/ipc/www/idb/idbprint.html
Nakagomi, O., & Cunliffe, N. A. (2007). Rotavirus vaccines: entering a new stage of deployment. Curr Opin Infect Dis 20(5):501–507.
Newall, A. T., MacIntyre, R., Wang, H., Hull, B., & Macartney, K. (2006). Burden of severe rotavirus disease in Australia. J Paediatr Child Health 42(9):521–527.
Parashar, U. D., Bresee, J. S., Gentsch, J. R., & Glass, R. I. (1998). Rotavirus. Emerg Infect Dis 4(4):561–570.
Podewils, L. J., Antil, L., Hummelman, E., Bresee, J., Parashar, U. D., & Rheingans, R. (2005). Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 192(Suppl 1):S133–145.
Rheingans, R. D., Constenla, D., Antil, L., Innis, B. L., & Breuer, T. (2007). Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 21(4):205–216.
Roberts, L. (2004). Vaccines. Rotavirus vaccines’ second chance. Science, 305(5692), 1890–1893.
Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices (ACIP)-recommended vaccination schedule – United States, February 2006–May 2007. (2008). MMWR Morb Mortal Wkly Rep 57(15):398–401.
Ruuska, T., & Vesikari, T. (1990). Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 22(3):259–267.
Velazquez, F. R., Matson, D. O., Calva, J. J., Guerrero, L., Morrow, A. L., Carter-Campbell, S., et al. (1996). Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335(14):1022–1028.
Vesikari, T., Giaquinto, C., & Huppertz, H. I. (2006). Clinical trials of rotavirus vaccines in Europe. Pediatr Infect Dis J 25(1 Suppl):S42–47.
Walker, D. G., & Rheingans, R. (2005). The cost–effectiveness of rotavirus vaccines. Expert Rev. Pharmacoeconomics Outcomes Res 5(5):593–601.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Shim, E., Castillo-Chavez, C. (2009). The Epidemiological Impact of Rotavirus Vaccination Programs in the United States and Mexico. In: Chowell, G., Hyman, J.M., Bettencourt, L.M.A., Castillo-Chavez, C. (eds) Mathematical and Statistical Estimation Approaches in Epidemiology. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2313-1_12
Download citation
DOI: https://doi.org/10.1007/978-90-481-2313-1_12
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2312-4
Online ISBN: 978-90-481-2313-1
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)